Abstract Number 639

BASECAMP-1: Leveraging HLA-A loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN logic-gated Tmod™ CAR T-cell therapy


Diane M. Simeone¹, M. Pia Morelli², J. Randolph Hecht³, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Kedar Kirtane⁶, Theodore H. Welling¹, Sandip P. Patel⁴, Marwan Fakih⁵, Sandip P. Patel⁴, Marwan Fakih⁵, Sandip P. Pate Caron Jacobson¹¹, Kirstin B. Liechty¹², Armen Mardiros¹², Ariane Lozac'hmeur¹³, Karl Beutner¹³, John S. Welch¹², Eric W. Ng¹², William Y. Go¹², David Maloney¹⁴, Scott Kopetz², Julian R. Molina⁷

the bastrointestive of California at Los Angeles, CA, USA; ³David Geffen School of Medical Oncology, University of California at Los Angeles, CA, USA; ³David Geffen School of Medicine at University of California at Los Angeles, CA, USA; ³David Geffen School of Medical Oncology, University of California at Los Angeles, CA, USA; ³David Geffen School of Medical Oncology, University of California at Los Angeles, CA, USA; ⁴Department of Medical Oncology, University of California at Los Angeles, CA, USA; ⁵City of Hope, Duarte, CA, USA; ⁴Department of Medical Oncology, University of California at Los Angeles, CA, USA; ⁵City of Hope, Duarte, CA, USA; ⁶H. Lee Moffitt Cancer Center, Tampa, FL, USA; ⁴Department of Medical Oncology, University of California at Los Angeles, CA, USA; ⁴Department of Medical Oncology, University of California at Los Angeles, CA, USA; ⁶H. Lee Moffitt Cancer Center, Tampa, FL, USA; ⁴Department of Medical Oncology, University of California at Los Angeles, CA, USA; ⁴Department of Redical Oncology, University of California at Los Angeles, CA, USA; ⁴Department of Redical Oncology, University of California at Los Angeles, CA, USA; ⁴Department of Redical Oncology, University of California at Los Angeles, CA, USA; ⁴Department of Redical Oncology, University of California at Los Angeles, CA, USA; ⁴Department of Redical Oncology, University of California at Los Angeles, CA, USA; ⁴Department of Redical Oncology, University of California at Los Angeles, CA, USA; ⁴Department of Redical Oncology, University of California at Los Angeles, CA, USA; ⁴Department of Redical Oncology, University of California at Los Angeles, CA, USA; ⁴Department of Redical Oncology, University of California at Los Angeles, CA, USA; ⁴Department of Redical Oncology, University of California at Los Angeles, CA, USA; ⁴Department of Redical Oncology, University of California at Los Angeles, CA, USA; ⁴Department of Redical Oncology, University of California at Los Angeles, CA, USA; ⁴Dep ¹⁰ All SA; ¹⁴ Clinical Research Division, Fred Hutchinson Cancer Center, Boston, MA, USA; ¹⁴ Clinical Research Center, Boston, MA, USA; ¹⁴ Clinical Research Division, Fred Hutchinson Cancer Research Center, Boston, MA, USA; ¹⁴ Clinical Research Center, Seattle, WA, USA; ¹⁴ Clinical Research Center, Boston, MA, USA; ¹⁴ Clinical Research Center, Boston, Center, Boston, Center, Boston, Center, Boston

BACKGROUND AND STUDY OBJECTIVES


- Solid tumors comprise >90% of cancers. Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic cancer (PANC) are the leading causes of cancer-related mortality (metastatic 5-year survival rate of 8%, 15%, and 3%, respectively) [1]
- Chimeric antigen receptor (CAR) T-cell therapy has demonstrated clinical outcomes in hematologic malignancies [2,3]. However, translating engineered T-cell therapies to solid tumors proves difficult due to a lack of tumor-specific targets that distinguish cancer cells from normal cells. In previous studies, the use of carcinoembryonic antigen (CEA) T-cell receptors and mesothelin (MSLN) CARs both resulted in dose-limiting on-target, off-tumor toxicities [4-6]
- Tmod™ CAR T-cell is a logic-gated cell therapy that addresses these challenges by leveraging dual receptors capable of killing tumor cells while leaving healthy cells intact [7]. Tmod platform technology is a versatile system that may be applied to T cells and natural killer cells in autologous and allogeneic settings
- A2B530 is a CEA-directed and A2B694 is an MSLN-directed Tmod construct both utilizing a leukocyte immunoglobulin-like receptor (LIR) 1-based inhibitory receptor (blocker) targeting HLA-A*02
- Human leukocyte antigen loss of heterozygosity (HLA LOH) may provide a means to distinguish between tumor and normal tissue in a definitive manner due to this irreversible, clonal loss within tumor cells [7,8]. The 2 receptors of the Tmod CAR T-cell platform comprise an activator that recognizes an antigen present on the surface of normal and tumor cells and a blocker that recognizes a second surface antigen from an HLA-A allele lost only in tumor cells
- Based on the Tempus xT real-world database, HLA-A LOH occurs in 12.2% to 26.0% of advanced solid tumors with an average of 16.3% in 10,867 samples tested [9]
- BASECAMP-1 is an ongoing study with the following key objectives: 1) To determine and identify patients with somatic HLA-A LOH eligible for Tmod CAR T-cell therapy and 2) subsequent leukapheresis and manufacturing feasibility for future Tmod CAR T-cell trials
- Eligible patients identified in BASECAMP-1 will be referred to the EVEREST A2B530 CEA Tmod and A2B694 MSLN Tmod interventional studies


STUDY RATIONALE



- HLA was selected as blocker target; first blocker HLA-A*02 is the most prevalent allele in the US population
- Activators include CEA and MSLN, which are both well-studied targets but have dose-limiting toxicities in previous studies
- CAR T HLA-A LOH approach is independently validated by Vogelstein/Kinzler, 2021 [8]

STUDY RATIONALE (cont.)






- 4-1BB)

Figure 3. Read coverage and B allele fraction (ratio of coverage for allele 1 and allele 2)

• A representative example of clonal HLA-A LOH (Figure 3), where a discordance is observed in read coverage of HLA-A*02:01 between the tumor and matched-normal samples [9, 11] HLA-A LOH can be reliably detected using the Tempus xT next-generation sequencing (NGS) assay (Table 1)

Figure 4. Higher tumor purity allows for more accurate prediction of HLA-A*02 LOH



20% 30% 40% 50%


Simulated Tumor Percentage



B2M shRNA, β2-microglobulin short-hairpin RNA; CEA, carcinoembryonic antigen; EF1a, elongation factor-1; HLA, human leukocyte antigen; LIR, leukocyte immunoglobulin-like receptor; LTR, long terminal repeat; MSLN, mesothelin; scFv, single-chain variable fragment; T2A, thosea asigna virus 2A CAR activator: 3rd-generation CAR T with both signal 1 (CD3ζ) and signal 2 activation domains (CD28 &

• CAR blocker: LIR-1 is a member of the immune inhibitory receptor family and contains 4 immunoreceptor tyrosine-based inhibition motifs in its signaling domain [10]


Replicant incompetent single lentivirus transgene: The activator and blocker receptors are co-expressed in a single construct containing a cleavable T2A linker (Figure 2)




STUDY RATIONALE (cont.)

Fable 1. Frequency of HLA-A LOH in advanced tumors ^a		
	Tempus HLA-A LOH advanced disease real-world [9]	TCGA HLA-A LOH primary tumors [12]
Average	16.3% (n=10,867)	12.6% (n=10,844)
Non-small cell lung cancer	23.1% (n=1,915)	25.3% (n=501)
lead and neck cancer	26.0% (n=208)	16.1% (n=522)
Breast cancer	12.2% (n=1,447)	13.6% (n=1,080)
Ovarian cancer	16.0% (n=569)	17.1% (n=579)
Colorectal cancer	15.6% (n=1,854)	9.6% (n=615)
Pancreatic cancer	19.6% (n=675)	33.1% (n=184)
Gastroesophageal cancer	20.8% (n=506)	16.2% (n=625)
lesothelioma	14.3% (n=7)	11.5% (n=87)

Figure 5. CEA Tmod (A2B530) in vitro study provides a therapeutic safety window comparable to NCI benchmark CEA TCR-T [4,13]






CEA, carcinoembryonic antigen; EC₅₀, half maximal effective concentration; E:T, effector to target; HLA, human leukocyte antigen; IC₅₀, half maximal inhibitory concentration; TCR, T-cell receptor; TPM, total particulate matter.

- CEA(+)A*02(-) colon cancer cell lines (**Figure 5A**) Mixed A*02(+) and A*02(-) cell cultures show Tmod's ability to discriminate between "normal" (A*02[+]) and
- tumor (A*02[-]) cells (**Figure 5B**)
- CEA and A*02 antigens, along with multiple cell lines

Figure 6. CEA Tmod (A2B530) in vivo study demonstrates potency comparable to NCI benchmark CEA TCR-T [4,13]



CAR, chimeric antigen receptor; CEA, carcinoembryonic antigen; HLA, human leukocyte antigen; TCR, T-cell receptor.

- In vivo studies show that Tmod maintains selectivity
- In order to allow for adequate tumor (HLA-A*02[-]) and "normal" (HLA-A*02[+]) cells to be established, tumo
- and "normal" cells were implanted subcutaneously in NOD scid gamma (NSG) mice CAR T cells or Tmod CAR T cells were administered via tail veins when tumor reached 100-150 mm³ (Day 0)
- regression of tumor grafts while "normal" tumor grafts continued to grow. Mice treated with CEA or MSLN CAR T cells (shown in green) experienced regressions of both tumor and "normal" tumor grafts (Figures 6 and 8)

HLA, human leukocyte antigen; LOH, loss of heterozygosity


40 60 80 90 40 60 80 90 40 60 80 90 No I OH

Simulated Tumor Purity

Tmod provided selectivity at varying effector-to-target (E:T) ratios with "normal" CEA(+)A*02(+) cells and tumor


CEA and HLA-A standard plots were generated using CEA surface expression data from mRNA data (Figure 5C) - CEA Tmod Jurkat or T-cell EC and IC were graphed with the tumor and normal expression values for the


Approximately 2 weeks following cell infusion, Tmod CAR T-cell treated mice (shown in red) experienced selective



(A) Cytotoxicity data of A2B694 constructs from a representative HI A-A* donor against three endogenous MSLN(+) cell lines with native or engineered expression of HLA-A*02. M5 CAR expressing cells are shown for comparison

benchmark MSLN CAR-T [14]





- Banked T cells will be available for subsequent autologous Tmod CAR T-cell therapy at the time of relapse

